US$ 28.94
aod9604 oral bioavailability AOD-9604 VIAL (5MG) Buy AOD-9604 Research Peptide |
Description
It is typically administered subcutaneously at 50100 mg daily in timed cycles, with noticeable energy and body-composition changes emerging within 38 weeks and side effects generally mild and transient

This means you receive care that is current, effective, and aligned with the most up-to-date research available

Bornstein, Hyperglycemic action of synthetic C-terminal fragments of human growth hormone

No, AOD-9604 is not FDA-approved for human therapeutic use
